Tissue transglutaminase: A novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 464-472

  Wilhelmus, Micha M M ^a   van Dam, Anne Marie ^a   Drukarch, Benjamin ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cross linking; Neurodegenerative disease; Protein aggregation; Tissue transglutaminase

Indexed keywords

2 [(2 OXOPROPYL)THIO]IMIDAZOLIUM DERIVATIVE; 3 HALO 4,5 4,5 DIHYDROISOXAZOLE DERIVATIVE; 6 (GAMMA GLUTAMYL)LYSINE; CADAVERINE; CALCIUM; CYSTAMINE; ENZYME INHIBITOR; HISTAMINE; IMIDAZOLE DERIVATIVE; IODOACETAMIDE; ISOXAZOLE DERIVATIVE; KCC 009; L 68277; L 682777; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PUTRESCINE; SPERMIDINE;

ALZHEIMER DISEASE; BRAIN FUNCTION; CATALYSIS; COVALENT BOND; CROSS LINKING; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME MECHANISM; GLIOMA; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ALZHEIMER DISEASE; ANIMALS; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TRANSGLUTAMINASES;

EID: 43049140462     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.059     Document Type: Review

References (126)

1. Achyuthan K.E., and Greenberg C.S. Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J. Biol. Chem. 262 (1987) 1901-1906
2. Aeschlimann D., and Paulsson M. Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb. Haemost. 71 (1994) 402-415
3. Aeschlimann D., and Thomazy V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect. Tissue Res. 41 (2000) 1-27
4. Akimov S.S., and Belkin A.M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98 (2001) 1567-1576
5. Ambrus A., Banyai I., Weiss M.S., Hilgenfeld R., Keresztessy Z., Muszbek L., and Fesus L. Calcium binding of transglutaminases: a 43Ca NMR study combined with surface polarity analysis. J. Biomol. Struct. Dyn. 19 (2001) 59-74
6. Andringa G., Lam K.Y., Chegary M., Wang X., Chase T.N., and Bennett M.C. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 18 (2004) 932-934
7. Appelt D.M., and Balin B.J. Analysis of paired helical filaments (PHFs) found in Alzheimer's disease using freeze-drying/rotary shadowing. J. Struct. Biol. 111 (1993) 85-95
8. Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Bacarra N.M., Romano D.M., Hartshorn M.A., Tanzi R.E., and Bush A.I. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273 (1998) 12817-12826
9. Bailey C.D., and Johnson G.V. Developmental regulation of tissue transglutaminase in the mouse forebrain. J. Neurochem. 91 (2004) 1369-1379
10. Bailey C.D., and Johnson G.V. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J. Neurochem. 92 (2005) 83-92
11. Balklava Z., Verderio E., Collighan R., Gross S., Adams J., and Griffin M. Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J. Biol. Chem. 277 (2002) 16567-16575
12. Barsigian C., Stern A.M., and Martinez J. Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators. J. Biol. Chem. 266 (1991) 22501-22509
13. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361 (2003) 1642-1644
14. Bergamini C.M., Dean M., Matteucci G., Hanau S., Tanfani F., Ferrari C., Boggian M., and Scatturin A. Conformational stability of human erythrocyte transglutaminase. Patterns of thermal unfolding at acid and alkaline pH. Eur. J. Biochem. 266 (1999) 575-582
15. Bergamini C.M., and Signorini M. In vivo inactivation of transglutaminase during the acute acrylamide toxic syndrome in the rat. Experientia 46 (1990) 278-281
16. Bruce S.E., Bjarnason I., and Peters T.J. Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin. Sci. (Lond.) 68 (1985) 573-579
17. Casadio R., Polverini E., Mariani P., Spinozzi F., Carsughi F., Fontana A., Polverino de L.P., Matteucci G., and Bergamini C.M. The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur. J. Biochem. 262 (1999) 672-679
18. Case A., and Stein R.L. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry 46 (2007) 1106-1115
19. Castillo G.M., Ngo C., Cummings J., Wight T.N., and Snow A.D. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. 69 (1997) 2452-2465
20. Choi K., Siegel M., Piper J.L., Yuan L., Cho E., Strnad P., Omary B., Rich K.M., and Khosla C. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol. 12 (2005) 469-475
21. Citron B.A., Suo Z., SantaCruz K., Davies P.J., Qin F., and Festoff B.W. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem. Int. 40 (2002) 69-78
22. Cotman S.L., Halfter W., and Cole G.J. Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol. Cell Neurosci. 15 (2000) 183-198
23. Cummings C.J., and Zoghbi H.Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet. 9 (2000) 909-916
24. de Cristofaro T., Affaitati A., Cariello L., Avvedimento E.V., and Varrone S. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates. Biochem. Biophys. Res. Commun. 260 (1999) 150-158
25. de Macedo P., Marrano C., and Keillor J.W. Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg. Med. Chem. 10 (2002) 355-360
26. de Macedo P., Marrano C., and Keillor J.W. A direct continuous spectrophotometric assay for transglutaminase activity. Anal. Biochem. 285 (2000) 16-20
27. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M., and Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22 (2002) 8942-8950
28. Dudek S.M., and Johnson G.V. Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res. 651 (1994) 129-133
29. Dudek S.M., and Johnson G.V. Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J. Neurochem. 61 (1993) 1159-1162
30. Duval E., Case A., Stein R.L., and Cuny G.D. Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 1885-1889
31. Eriksson S., Janciauskiene S., and Lannfelt L. Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2313-2317
32. Fesus L. Biochemical events in naturally occurring forms of cell death. FEBS Lett. 328 (1993) 1-5
33. Folk J.E., and Cole P.W. Identification of a functional cysteine essential for the activity of guinea pig liver transglutaminase. J. Biol. Chem. 241 (1966) 3238-3240
34. Folk J.E., and Finlayson J.S. The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem. 31 (1977) 1-133
35. Fonte V., Kapulkin V., Taft A., Fluet A., Friedman D., and Link C.D. Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9439-9444
36. Fox B.A., Yee V.C., Pedersen L.C., Le I T., Bishop P.D., Stenkamp R.E., and Teller D.C. Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by X-ray crystallography. J. Biol. Chem. 274 (1999) 4917-4923
37. Freund K.F., Doshi K.P., Gaul S.L., Claremon D.A., Remy D.C., Baldwin J.J., Pitzenberger S.M., and Stern A.M. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 33 (1994) 10109-10119
38. Gaudry C.A., Verderio E., Aeschlimann D., Cox A., Smith C., and Griffin M. Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain. J. Biol. Chem. 274 (1999) 30707-30714
39. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
40. Greenberg C.S., Birckbichler P.J., and Rice R.H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 5 (1991) 3071-3077
41. Griffin M., Casadio R., and Bergamini C.M. Transglutaminases: nature's biological glues. Biochem. J. 368 (2002) 377-396
42. Halim D., Caron K., and Keillor J.W. Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 305-308
43. Harper J.D., and Lansbury Jr. P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66 (1997) 385-407
44. Hausch F., Halttunen T., Maki M., and Khosla C. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem. Biol. 10 (2003) 225-231
45. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Vonsattel J.P., Tanzi R.E., and Bush A.I. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272 (1997) 26464-26470
46. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., and Tsuji S. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18 (1998) 111-117
47. Iismaa S.E., Wu M.J., Nanda N., Church W.B., and Graham R.M. GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. J. Biol. Chem. 275 (2000) 18259-18265
48. Jeitner T.M., Bogdanov M.B., Matson W.R., Daikhin Y., Yudkoff M., Folk J.E., Steinman L., Browne S.E., Beal M.F., Blass J.P., and Cooper A.J. N(epsilon)-(gamma-l-glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J. Neurochem. 79 (2001) 1109-1112
49. Jensen P.H., Sorensen E.S., Petersen T.E., Gliemann J., and Rasmussen L.K. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem. J. 310 Pt 1 (1995) 91-94
50. Johnson G.V., Cox T.M., Lockhart J.P., Zinnerman M.D., Miller M.L., and Powers R.E. Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res. 751 (1997) 323-329
51. Jones R.A., Nicholas B., Mian S., Davies P.J., and Griffin M. Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J. Cell Sci. 110 Pt 19 (1997) 2461-2472
52. Junn E., Ronchetti R.D., Quezado M.M., Kim S.Y., and Mouradian M.M. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2047-2052
53. Kahlem P., Green H., and Djian P. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1 (1998) 595-601
54. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., and Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 (2002) 143-149
55. Karpuj M.V., Garren H., Slunt H., Price D.L., Gusella J., Becher M.W., and Steinman L. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7388-7393
56. Killackey J.J., Bonaventura B.J., Castelhano A.L., Billedeau R.J., Farmer W., DeYoung L., Krantz A., and Pliura D.H. A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes. Mol. Pharmacol. 35 (1989) 701-706
57. Kim S.Y., Grant P., Lee J.H., Pant H.C., and Steinert P.M. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 274 (1999) 30715-30721
58. Kleman J.P., Aeschlimann D., Paulsson M., and van der R.M. Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Biochemistry 34 (1995) 13768-13775
59. Konno T., Morii T., Hirata A., Sato S., Oiki S., and Ikura K. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 44 (2005) 2072-2079
60. Korponay-Szabo I.R., Laurila K., Szondy Z., Halttunen T., Szalai Z., Dahlbom I., Rantala I., Kovacs J.B., Fesus L., and Maki M. Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. Gut 52 (2003) 199-204
61. Lai T.S., Bielawska A., Peoples K.A., Hannun Y.A., and Greenberg C.S. Sphingosylphosphocholine reduces the calcium ion requirement for activating tissue transglutaminase. J. Biol. Chem. 272 (1997) 16295-16300
62. Lai T.S., Hausladen A., Slaughter T.F., Eu J.P., Stamler J.S., and Greenberg C.S. Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40 (2001) 4904-4910
63. Lai T.S., Slaughter T.F., Koropchak C.M., Haroon Z.A., and Greenberg C.S. C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity. J. Biol. Chem. 271 (1996) 31191-31195
64. Lai T.S., Slaughter T.F., Peoples K.A., Hettasch J.M., and Greenberg C.S. Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes. Identification of distinct binding sites for Mg-GTP and Mg-ATP. J. Biol. Chem. 273 (1998) 1776-1781
65. Lai T.S., Tucker T., Burke J.R., Strittmatter W.J., and Greenberg C.S. Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J. Neurochem. 88 (2004) 1253-1260
66. Leavitt B.R., Guttman J.A., Hodgson J.G., Kimel G.H., Singaraja R., Vogl A.W., and Hayden M.R. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 68 (2001) 313-324
67. Lee V.M., Balin B.J., Otvos Jr. L., and Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251 (1991) 675-678
68. Lesort M., Attanavanich K., Zhang J., and Johnson G.V. Distinct nuclear localization and activity of tissue transglutaminase. J. Biol. Chem. 273 (1998) 11991-11994
69. Lesort M., Chun W., Johnson G.V., and Ferrante R.J. Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 73 (1999) 2018-2027
70. Lesort M., Lee M., Tucholski J., and Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278 (2003) 3825-3830
71. Lorand L. DRPLA aggregation and transglutaminase, revisited. Nat. Genet. 20 (1998) 231
72. Lorand L., and Conrad S.M. Transglutaminases. Mol. Cell Biochem. 58 (1984) 9-35
73. Lorand L., and Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4 (2003) 140-156
74. Ma J., Yee A., Brewer Jr. H.B., Das S., and Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372 (1994) 92-94
75. Maccioni R.B., and Seeds N.W. Transglutaminase and neuronal differentiation. Mol. Cell Biochem. 69 (1986) 161-168
76. Magrane J., Smith R.C., Walsh K., and Querfurth H.W. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J. Neurosci. 24 (2004) 1700-1706
77. Mahoney S.A., Wilkinson M., Smith S., and Haynes L.W. Stabilization of neurites in cerebellar granule cells by transglutaminase activity: identification of midkine and galectin-3 as substrates. Neuroscience 101 (2000) 141-155
78. Maiuri L., Ciacci C., Ricciardelli I., Vacca L., Raia V., Rispo A., Griffin M., Issekutz T., Quaratino S., and Londei M. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 129 (2005) 1400-1413
79. Marrano C., de, M.P., Gagnon P., Lapierre D., Gravel C., and Keillor J.W. Synthesis and evaluation of novel dipeptide-bound 1,2,4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg. Med. Chem. 9 (2001) 3231-3241
80. Marrano C., de, M.P., and Keillor J.W. Evaluation of novel dipeptide-bound alpha,beta-unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg. Med. Chem. 9 (2001) 1923-1928
81. Martinez J., Rich E., and Barsigian C. Transglutaminase-mediated cross-linking of fibrinogen by human umbilical vein endothelial cells. J. Biol. Chem. 264 (1989) 20502-20508
82. Mastroberardino P.G., Iannicola C., Nardacci R., Bernassola F., de Laurenzi V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L., and Piacentini M. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9 (2002) 873-880
83. Miller M.L., and Johnson G.V. Transglutaminase cross-linking of the tau protein. J. Neurochem. 65 (1995) 1760-1770
84. Mosher D.F. Cross-linking of fibronectin to collagenous proteins. Mol. Cell Biochem. 58 (1984) 63-68
85. Muma N.A. Transglutaminase is linked to neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 66 (2007) 258-263
86. Nardacci R., Lo I.O., Ciccosanti F., Falasca L., Addesso M., Amendola A., Antonucci G., Craxi A., Fimia G.M., Iadevaia V., Melino G., Ruco L., Tocci G., Ippolito G., and Piacentini M. Transglutaminase type II plays a protective role in hepatic injury. Am. J. Pathol. 162 (2003) 1293-1303
87. Nemes Z., Devreese B., Steinert P.M., Van B.J., and Fesus L. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J. 18 (2004) 1135-1137
88. Norlund M.A., Lee J.M., Zainelli G.M., and Muma N.A. Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res. 851 (1999) 154-163
89. Pardin C., Gillet S.M., and Keillor J.W. Synthesis and evaluation of peptidic irreversible inhibitors of tissue transglutaminase. Bioorg. Med. Chem. 14 (2006) 8379-8385
90. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
91. Pisano J.J., Finlayson J.S., and Peyton M.P. Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine. Science 160 (1968) 892-893
92. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
93. Ruan Q., and Johnson G.V. Transglutaminase 2 in neurodegenerative disorders. Front Biosci. 12 (2007) 891-904
94. Sane D.C., Moser T.L., Pippen A.M., Parker C.J., Achyuthan K.E., and Greenberg C.S. Vitronectin is a substrate for transglutaminases. Biochem. Biophys. Res. Commun. 157 (1988) 115-120
95. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
96. Selkoe D.J. The origins of Alzheimer disease: a is for amyloid. JAMA 283 (2000) 1615-1617
97. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275 (1997) 630-631
98. Singer S.M., Zainelli G.M., Norlund M.A., Lee J.M., and Muma N.A. Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem. Int. 40 (2002) 17-30
99. Singh U.S., Pan J., Kao Y.L., Joshi S., Young K.L., and Baker K.M. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J. Biol. Chem. 278 (2003) 391-399
100. Sollid L.M., and Khosla C. Future therapeutic options for celiac disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 140-147
101. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
102. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 1977-1981
103. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., and Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8098-8102
104. Tso J.Y., Bower S.G., and Zalkin H. Mechanism of inactivation of glutamine amidotransferases by the antitumor drug l-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). J. Biol. Chem. 255 (1980) 6734-6738
105. Tucholski J., Kuret J., and Johnson G.V. Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J. Neurochem. 73 (1999) 1871-1880
106. Tucholski J., Lesort M., and Johnson G.V. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 102 (2001) 481-491
107. Upchurch H.F., Conway E., Patterson Jr. M.K., Birckbichler P.J., and Maxwell M.D. Cellular transglutaminase has affinity for extracellular matrix. In Vitro Cell Dev. Biol. 23 (1987) 795-800
108. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001) 44284-44296
109. Verderio E., Nicholas B., Gross S., and Griffin M. Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment, and cell death. Exp. Cell Res. 239 (1998) 119-138
110. Wakshlag J.J., Antonyak M.A., Boehm J.E., Boehm K., and Cerione R.A. Effects of tissue transglutaminase on beta-amyloid1-42-induced apoptosis. Protein J. 25 (2006) 83-94
111. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274 (1999) 25945-25952
112. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
113. Walther D.J., Peter J.U., Winter S., Holtje M., Paulmann N., Grohmann M., Vowinckel J., amo-Bethencourt V., Wilhelm C.S., hnert-Hilger G., and Bader M. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115 (2003) 851-862
114. Watts R.E., Siegel M., and Khosla C. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J. Med. Chem. 49 (2006) 7493-7501
115. Webster S., Bonnell B., and Rogers J. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 150 (1997) 1531-1536
116. Webster S., Bradt B., Rogers J., and Cooper N. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J. Neurochem. 69 (1997) 388-398
117. Weiss M.S., Metzner H.J., and Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. 423 (1998) 291-296
118. Wilhelmus M.M., Boelens W.C., Otte-Holler I., Kamps B., de Waal R.M., and Verbeek M.M. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res. 1089 (2006) 67-78
119. Wilhelmus M.M., Boelens W.C., Otte-Holler I., Kamps B., Kusters B., Maat-Schieman M.L., de Waal R.M., and Verbeek M.M. Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol. (Berl) 111 (2006) 139-149
120. Wilhelmus M.M., de Waal R.M., and Verbeek M.M. Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease. Mol. Neurobiol. 35 (2007) 203-216
121. Wilhelmus M.M., Otte-Holler I., Davis J., Van Nostrand W.E., de Waal R.M., and Verbeek M.M. Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. J. Neurosci. 25 (2005) 3621-3627
122. Yee V.C., Pedersen L.C., Le I T., Bishop P.D., Stenkamp R.E., and Teller D.C. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7296-7300
123. Yuan L., Siegel M., Choi K., Khosla C., Miller C.R., Jackson E.N., Piwnica-Worms D., and Rich K.M. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26 (2007) 2563-2573
124. Zainelli G.M., Ross C.A., Troncoso J.C., and Muma N.A. Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J. Neuropathol. Exp. Neurol. 62 (2003) 14-24
125. Zhang J., Lesort M., Guttmann R.P., and Johnson G.V. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 273 (1998) 2288-2295
126. Zhang W., Johnson B.R., Suri D.E., Martinez J., and Bjornsson T.D. Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques. Acta Neuropathol. (Berl) 96 (1998) 395-400